Neuropeptide y and its Y2 receptor: Potential targets in neuroblastoma therapy

Oncogene

Volumn 29, Issue 41, 2010, Pages 5630-5642

  Lu, C ^a   Everhart, L ^a   Tilan, J ^a   Kuo, L ^a   Sun, C C J ^b   Munivenkatappa, R B ^b   Jonsson Rylander A C ^c   Sun, J ^d   Kuan Celarier, A ^a   Li, L ^a   Abe, K ^e   Zukowska, Z ^a   Toretsky, J A ^f   Kitlinska, J ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c ASTRAZENECA R AND D   (Sweden)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^f GEORGETOWN UNIVERSITY   (United States)

Author keywords

angiogenesis; neuroblastoma; neuropeptide Y

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; N [2 [1,2 DIHYDRO 3,5(4H) DIOXO 1,2 DIPHENYL 1,2,4 TRIAZOL 4 YL]ETHYL] N2 [[1 [2 [4 [5,11 DIHYDRO 6(6H) OXODIBENZ[B,E]AZEPIN 11 YL] 1 PIPERAZINYL] 2 OXOETHYL]CYCLOPENTYL]ACETYL]ARGININAMIDE; NEUROPEPTIDE Y; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; NEUROPEPTIDE Y2 RECEPTOR; SMALL INTERFERING RNA;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN TISSUE; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; VASCULARIZATION;

ANIMALS; APOPTOSIS; ARGININE; BENZAZEPINES; BLOTTING, WESTERN; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOVASCULARIZATION, PATHOLOGIC; NEUROBLASTOMA; NEUROPEPTIDE Y; RECEPTORS, NEUROPEPTIDE Y; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77958017639     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.301     Document Type: Article

References (42)

1. Biedler JL, Roffler-Tarlov S, Schachner M, Freedman LS. (1978). Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. Cancer Res 38: 3751-3757.
2. Chen Y, Takita J, Choi YL, Kato M, Ohira M, Sanada M et al. (2008). Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455: 971-974.
3. Cohen PS, Cooper MJ, Helman LJ, Thiele CJ, Seeger RC, Israel MA. (1990). Neuropeptide Y expression in the developing adrenal gland and in childhood neuroblastoma tumors. Cancer Res 50: 6055-6061.
4. Dotsch J, Christiansen H, Hanze J, Lampert F, Rascher W. (1998). Plasma neuropeptide Y of children with neuroblastoma in relation to stage, age and prognosis, and tissue neuropeptide Y. Regul Pept 75-76: 185-190.
5. Ekstrand AJ, Cao R, Bjorndahl M, Nystrom S, Jonsson-Rylander AC, Hassani H et al. (2003). Deletion of neuropeptide Y (NPY) 2 receptor in mice results in blockage of NPY-induced angiogenesis and delayed wound healing. Proc Natl Acad Sci USA 100: 6033-6038.
6. George RE, Sanda T, Hanna M, Frohling S, Luther II W, Zhang J et al. (2008). Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455: 975-978.
7. Hansel DE, Eipper BA, Ronnett GV. (2001). Neuropeptide Y functions as a neuroproliferative factor. Nature 410: 940-944.
8. Jonsson-Rylander AC, Nordlander M, Svindland A, Ilebekk A. (2003). Distribution of neuropeptide Y Y1 and Y2 receptors in the postmortem human heart. Peptides 24: 255-262.
9. Kitlinska J, Abe K, Kuo L, Pons J, Yu M, Li L et al. (2005). Differential effects of neuropeptide Y on the growth and vascularization of neural crest-derived tumors. Cancer Res 65: 1719-1728.
10. Kitlinska J, Lee EW, Movafagh S, Pons J, Zukowska Z. (2002). Neuropeptide Y-induced angiogenesis in aging. Peptides 23: 71-77.
11. Kogner P, Bjork O, Theodorsson E. (1994). Plasma neuropeptide Y in healthy children: influence of age, anaesthesia and the establishment of an age-adjusted reference interval. Acta Paediatr 83: 423-427.
12. Korner M, Waser B, Reubi JC. (2004). High expression of neuropep-tide Y receptors in tumors of the human adrenal gland and extra-adrenal paraganglia. Clin Cancer Res 10: 8426-8433.
13. Koulu M, Movafagh S, Tuohimaa J, Jaakkola U, Kallio J, Pesonen U et al. (2004). Neuropeptide Y and Y2-receptor are involved in development of diabetic retinopathy and retinal neovascularization. Ann Med 36: 232-240.
14. Lee EW, Grant DS, Movafagh S, Zukowska Z. (2003a). Impaired angiogenesis in neuropeptide Y (NPY)-Y2 receptor knockout mice. Peptides 24: 99-106.
15. Lee EW, Michalkiewicz M, Kitlinska J, Kalezic I, Switalska H, Yoo P et al. (2003b). Neuropeptide Y induces ischemic angiogenesis and restores function of ischemic skeletal muscles. J Clin Invest 111: 1853-1862.
16. Lei K, Davis RJ. (2003). JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis. Proc Natl Acad Sci USA 100: 2432-2437.
17. Ley R, Balmanno K, Hadfield K, Weston C, Cook SJ. (2003). Activation of the ERK1/2 signaling pathway promotes phosphor-ylation and proteasome-dependent degradation of the BH3-only protein, Bim. J Biol Chem 278: 18811-18816.
18. Li Z, Zhang J, Liu Z, Woo CW, Thiele CJ. (2007). Downregulation of Bim by brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from paclitaxel but not etoposide or cisplatin-induced cell death. Cell Death Differ 14: 318-326.
19. Magni P, Beretta E, Scaccianoce E, Motta M. (2000). Retinoic acid negatively regulates neuropeptide Y expression in human neuro-blastoma cells. Neuropharmacology 39: 1628-1636.
20. Malmstrom RE. (2001). Vascular pharmacology of BIIE0246, the first selective non-peptide neuropeptide Y Y(2) receptor antagonist, in vivo. Br J Pharmacol 133: 1073-1080.
21. Maris JM. (2005). The biologic basis for neuroblastoma heterogeneity and risk stratification. Curr Opin Pediatr 17: 7-13.
22. Maris JM, Hogarty MD, Bagatell R, Cohn SL. (2007). Neuro-blastoma. Lancet 369: 2106-2120.
23. Meitar D, Crawford SE, Rademaker AW, Cohn SL. (1996). Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J Clin Oncol 14: 405-414.
24. Mosse YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF et al. (2008). Identification of ALK as a major familial neuroblas-toma predisposition gene. Nature 455: 930-935.
25. Movafagh S, Hobson JP, Spiegel S, Kleinman HK, Zukowska Z. (2006). Neuropeptide Y induces migration, proliferation, and tube formation of endothelial cells bimodally via Y1, Y2, and Y5 receptors. FASEB J 20: 1924-1926.
26. Naveilhan P, Hassani H, Canals JM, Ekstrand AJ, Larefalk A, Chhajlani V et al. (1999). Normal feeding behavior, body weight and leptin response require the neuropeptide Y Y2 receptor. Nat Med 5: 1188-1193.
27. O'Hare MM, Schwartz TW. (1989a). Expression and precursor processing of neuropeptide Y in human and murine neuroblastoma and pheochromocytoma cell lines. Cancer Res 49: 7015-7019.
28. O'Hare MM, Schwartz TW. (1989b). Expression and precursor processing of neuropeptide Y in human pheochromocytoma and neuroblastoma tumors. Cancer Res 49: 7010-7014.
29. Park JR, Eggert A, Caron H. (2008). Neuroblastoma: biology, prognosis, and treatment. Pediatr Clin N Am 55: 97-120.
30. Pons J, Kitlinska J, Jacques D, Perreault C, Nader M, Everhart L et al. (2008). Interactions of multiple signaling pathways in neuropeptide Y-mediated bimodal vascular smooth muscle cell growth. Can J Physiol Pharmacol 86: 438-448.
31. Pons J, Kitlinska J, Ji H, Lee EW, Zukowska Z. (2003). Mitogenic actions of neuropeptide Y in vascular smooth muscle cells: synergetic interactions with the beta-adrenergic system. Can J Physiol Pharmacol 81: 177-185.
32. Putcha GV, Le S, Frank S, Besirli CG, Clark K, Chu B et al. (2003). JNK-mediated BIM phosphorylation potentiates BAX-dependent apoptosis. Neuron 38: 899-914.
33. Ribatti D, Ponzoni M. (2005). Antiangiogenic strategies in neuro-blastoma. Cancer Treat Rev 31: 27-34.
34. Rossler J, Taylor M, Geoerger B, Farace F, Lagodny J, Peschka-Suss R et al. (2008). Angiogenesis as a target in neuroblastoma. Eur J Cancer 44: 1645-1656.
35. Sheriff S, Dayal R, Kasckow J, Regmi A, Chance W, Fischer J et al. (1998). NPY upregulates genes containing cyclic AMP response element in human neuroblastoma cell lines bearing Y1 and Y2 receptors: involvement of CREB. Regul Pept 75-76: 309-318.
36. Shusterman S, Maris JM. (2005). Prospects for therapeutic inhibition of neuroblastoma angiogenesis. Cancer Lett 228: 171-179.
37. Uddman R, Moller S, Nilsson T, Nystrom S, Ekstrand J, Edvinsson L. (2002). Neuropeptide Y Y1 and neuropeptide Y Y2 receptors in human cardiovascular tissues. Peptides 23: 927-934.
38. Wassberg E. (1999). Angiostatic treatment of neuroblastoma. Ups J Med Sci 104: 1-24.
39. Whitfield J, Neame SJ, Paquet L, Bernard O, Ham J. (2001). Dominant-negative c-Jun promotes neuronal survival by reducing BIM expression and inhibiting mitochondrial cytochrome c release. Neuron 29: 629-643.
40. Yoon HZ, Yan Y, Geng Y, Higgins RD. (2002). Neuropeptide Y expression in a mouse model of oxygen-induced retinopathy. Clin Experiment Ophthalmol 30: 424-429.
41. Zukowska-Grojec Z, Karwatowska-Prokopczuk E, Rose W, Rone J, Movafagh S, Ji H et al. (1998). Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium. Circ Res 83: 187-195.
42. Zukowska-Grojec Z, Pruszczyk P, Colton C, Yao J, Shen GH, Myers AK et al. (1993). Mitogenic effect of neuropeptide Y in rat vascular smooth muscle cells. Peptides 14: 263-268.